Dr Choueiri Highlights Nivolumab Plus Cabozantinib vs Sunitinib for Advanced RCC


Toni Choueiri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, shares results from a new analysis of the phase 3 Checkmate 9ER trial of cabozantinib combined with nivolumab for the first-line treatment of advanced renal cell carcinoma (RCC). These data were presented at the 2021 Virtual ASCO Genitourinary Cancers Symposium. 


Stay in the know.
OncNet Newsletter